News|Articles|October 9, 2025
Streamline AAV-based Gene Therapies with High-Performing Off-the-Shelf Plasmids
Author(s)Catalent
Key Takeaways
Optimized plasmids are vital for viral vector production. Catalent’s off-the-shelf plasmids help AAV gene therapy developers enhance efficiency, reduce costs, and improve consistency across development and manufacturing.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Trending on BioPharm International
1
BioPharma By The Numbers: Batch Failures in Biopharma Manufacturing
2
Charles River Incubator Cohort to Accelerate CGT Development
3
Developing Next-Gen Cell Lines Using Targeted Integration
4
Two-Minute Mysteries: BioPharm Stories - Episode 2: The Costly Myth of Noninvasive Glucose Monitoring
5
